Androgen Deprivation Therapy Clinical Trial
Official title:
Phase IB Trial of Relugolix and Enzalutamide as Neoadjuvant/ Adjuvant to Local-regional Treatment in Patients With High-risk Locally Advanced Prostate CAncer (RENAPCA)
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the chances of curing the cancer and make the patients live longer without the cancer getting worse. The main questions we want to answer in this study are: - Can using relugolix and enzalutamide together help increase the chances of curing high-risk advanced prostate cancer? - Does this combination treatment help patients live longer without their cancer getting worse? Participants in this study will be asked to take relugolix and enzalutamide as part of their cancer treatment. They will also undergo Radiation Therapy or prostatectomy, which are standard treatments for this type of cancer.
This clinical trial aims to assess the effectiveness and safety of combining relugolix and enzalutamide as neoadjuvant and adjuvant androgen deprivation therapy (ADT) in patients diagnosed with high-risk locally advanced prostate cancer who are also candidates for definitive radiation therapy (RT) or surgical treatment. The objectives of this phase Ib clinical trial are to evaluate the efficacy, safety, and dynamic changes in biomarkers associated with this combination therapy. A combined total of up to 41 evaluable patients will participate in this study, with the initial safety lead-in cohorts involving a potential enrollment of 12 patients, followed by a dose expansion cohort that may include up to 29 subjects. The combined treatment cycle spans 28 days, with patients receiving six months of neoadjuvant therapy followed by an additional 18 months in the adjuvant setting. Treatment duration may be shortened if unacceptable toxicity occurs or if a patient withdraws consent. Approximately 24 months of post-accrual follow-up are anticipated to adequately assess the efficacy and safety of the treatment. Ultimately, the study aims to contribute valuable insights into the potential benefits of neoadjuvant and adjuvant hormonal therapy with relugolix plus enzalutamide in improving outcomes for patients facing high-risk locally advanced prostate cancer. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03440879 -
Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose
|
N/A | |
Recruiting |
NCT05700903 -
Contributions to Hypertension With Androgen Deprivation Therapy
|
Phase 4 | |
Completed |
NCT01711892 -
Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy
|
N/A | |
Recruiting |
NCT05781217 -
Short Versus Long-term Androgen Deprivation Therapy With Salvage Radiotherapy in Prostate Cancer. URONCOR 0624
|
Phase 3 | |
Active, not recruiting |
NCT04062162 -
Walking Football as a Supportive Medicine for Patients With Prostate Cancer
|
N/A | |
Recruiting |
NCT03845751 -
EvaluatioN of HIFU Hemiablation and Short Term AndrogeN Deprivation Therapy Combination to Enhance Prostate Cancer Control.
|
Phase 2 | |
Active, not recruiting |
NCT03867357 -
Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia
|
||
Completed |
NCT02631681 -
Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy
|
N/A | |
Recruiting |
NCT00957606 -
Osteoporosis Among Men Treated With Androgen Deprivation for Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05327465 -
Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
|
N/A | |
Completed |
NCT04500080 -
Feasibility and Safety of Physical Exercise in Men With Prostate Cancer
|
N/A | |
Completed |
NCT03672396 -
Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer
|
N/A |